Printer Friendly

Absence of Alternative Therapies for Psoriatic Arthritis Signifies a Vast Untouched Market, Finds Frost & Sullivan.

- Pharmaceutical companies need to introduce safe and effective therapies for patients that do not respond to TNF inhibitors

MOUNTAIN VIEW, California, Oct. 25, 2012 /PRNewswire/ -- Tumor necrosis factor (TNF) inhibitors are currently the only therapeutic class available to psoriatic arthritis (PsA) patients in need of additional therapy beyond standard of care. This represents a significant unmet need for alternative therapies for TNF inhibitor refractory patients.

New analysis from Frost & Sullivan's ( United States Market for Psoriatic Arthritis Pharmacotherapy research finds that psoriatic arthritis pharmacotherapeutics prescribed as add-on therapies to standard background therapy earned revenues of approximately $751.5 million in 2011. Frost & Sullivan estimates this to reach $1.3 billion in 2017.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

TNF inhibitors, a well-established drug class, have laid the groundwork for the next-generation of effective disease modifying antirheumatic drugs and biologics with improved safety and efficacy profiles. The development of novel therapies for this complex disease, however, is hindered by several factors, such as an incompletely understood pathogenesis and a perception that PsA is a milder disease than rheumatoid arthritis. In addition, dermatologists may be less inclined than rheumatologists to prescribe biologics, hindering acceptance of these valuable treatments within the physician community. Consequently, TNF inhibitors are likely to continue as the first line of treatment for PsA, initially limiting the uptake of new agents to second line use.

"While some TNF inhibitors that are effective in rheumatoid arthritis are also effective in PsA, patients with moderate to severe forms of the disease may not always respond to them," said Frost & Sullivan Senior Industry Analyst Debbie Toscano. "This creates a strong need for alternative therapies."

To improve their therapies' commercial acceptance, pharmaceutical companies need to raise the level of disease awareness and alter the perception of the potential severity of PsA. In addition, robust data supporting the clinical benefits of new agents in comparison with TNF inhibitors can help to overcome the entrenchment of this class and win over payers, prescribers and patients.

"With the impending launch of three new therapies for the treatment of PsA in 2014, the awareness of PsA is expected to increase substantially," noted Toscano. "This will renew interest in PsA, as patients and physicians will finally be presented with alternative treatments."

United States Market for Psoriatic Arthritis Pharmacotherapy is part of the Life Sciences Growth Partnership Services program, which also includes research in the following markets: United States Market for Rheumatoid Arthritis Pharmacotherapy, United States Rheumatic Diseases Therapeutics Market, United States Market for Ankylosing Spondylitis Pharmacotherapy, and U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

* The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

* The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion

Join Us: Join our community

Subscribe: Newsletter on "the next big thing"

Register: Gain access to visionary innovation

United States Market for Psoriatic Arthritis Pharmacotherapy NB3A-52

Contact: Britni Myers Corporate Communications - North America P: +1-210-477-8481 F: +1-210-348-1003 E:
COPYRIGHT 2012 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Date:Oct 25, 2012
Previous Article:Economic Uncertainty Hinders the Investment Environment in the Aerospace and Defense Industry, Finds Frost & Sullivan.
Next Article:Is Hidden Food or Drink Intolerance Holding You Back? Discover Your Own Performance Enhancing Diet!

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters